8-K: Cognition Therapeutics Receives Extension to Regain Nasdaq Compliance

Cognition Therapeutics has been granted an extension by Nasdaq to regain compliance with the minimum bid price requirement, with its stock being transferred to the Nasdaq Capital Market.

Summary

• Cognition Therapeutics received notice from Nasdaq on September 12, 2024, that its stock price was below the required $1.00 per share for continued listing.
• The company was initially given until March 11, 2025, to regain compliance.
• On March 12, 2025, Nasdaq granted Cognition Therapeutics an extension until September 8, 2025, to meet the minimum bid price requirement.
• The company's stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective March 14, 2025.
• If the stock price reaches at least $1.00 per share for 10 consecutive business days before September 8, 2025, Nasdaq will confirm compliance.
• Failure to comply by September 8, 2025, may result in delisting, which the company can appeal.
• Cognition Therapeutics is considering options such as a reverse stock split to regain compliance.
• There is no guarantee that the company will regain compliance or avoid delisting.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the company's non-compliance with Nasdaq listing requirements, although the extension provides some hope. The risk of delisting remains a concern.

Positives

• Nasdaq granted an extension, providing Cognition Therapeutics more time to regain compliance.
• The company has the option to appeal a delisting determination.

Negatives

• Cognition Therapeutics' stock price has been below the minimum $1.00 per share, leading to the compliance issue.
• There is no assurance that the company will regain compliance or avoid delisting.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price rule could lead to delisting.
• The company's stock price may not reach the required $1.00 per share within the extension period.
• A reverse stock split may negatively impact shareholders.

Future Outlook

Cognition Therapeutics intends to actively monitor its stock price and consider available options, including a reverse stock split, to regain compliance with Nasdaq listing rules.

Management Comments

• The Company intends to continue to actively monitor the bid price for its common stock between now and September 8, 2025, and will consider available options to resolve the deficiency and regain compliance with the Rule.

Industry Context

Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance due to volatile stock prices and the inherent risks associated with drug development. Extensions are not uncommon, but ultimate success depends on positive clinical trial results, partnerships, or other catalysts that can drive up the stock price.

Comparison to Industry Standards

• Companies like Cassava Sciences (SAVA) and Anavex Life Sciences (AVXL), also in the Alzheimer's space, have experienced significant stock price volatility based on clinical trial data, demonstrating the sensitivity of biotech stocks to research outcomes.
• Reverse stock splits are a common strategy employed by companies facing delisting, but their effectiveness varies depending on investor perception and underlying business fundamentals.
• The Nasdaq Capital Market has less stringent requirements than the Global Market, providing some relief but also potentially signaling increased risk to investors.

Stakeholder Impact

• Shareholders face the risk of further stock price decline and potential delisting.
• Employees may experience uncertainty due to the company's financial situation.
• The company's ability to raise capital and fund research may be affected.

Next Steps

• Cognition Therapeutics will monitor its stock price.
• Cognition Therapeutics will consider options to resolve the deficiency and regain compliance.
• Cognition Therapeutics may effect a reverse stock split.

Key Dates